These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20137931)

  • 1. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.
    Meyers MJ; Pelc M; Kamtekar S; Day J; Poda GI; Hall MK; Michener ML; Reitz BA; Mathis KJ; Pierce BS; Parikh MD; Mischke DA; Long SA; Parlow JJ; Anderson DR; Thorarensen A
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1543-7. PubMed ID: 20137931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
    Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
    Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.
    Simard JR; Getlik M; Grütter C; Schneider R; Wulfert S; Rauh D
    J Am Chem Soc; 2010 Mar; 132(12):4152-60. PubMed ID: 20201574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor.
    Scott DA; Dakin LA; Del Valle DJ; Diebold RB; Drew L; Gero TW; Ogoe CA; Omer CA; Repik G; Thakur K; Ye Q; Zheng X
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1382-4. PubMed ID: 21295474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
    Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase.
    Scott DA; Balliet CL; Cook DJ; Davies AM; Gero TW; Omer CA; Poondru S; Theoclitou ME; Tyurin B; Zinda MJ
    Bioorg Med Chem Lett; 2009 Feb; 19(3):697-700. PubMed ID: 19112018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
    J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
    Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
    J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping.
    Richardson CM; Nunns CL; Williamson DS; Parratt MJ; Dokurno P; Howes R; Borgognoni J; Drysdale MJ; Finch H; Hubbard RE; Jackson PS; Kierstan P; Lentzen G; Moore JD; Murray JB; Simmonite H; Surgenor AE; Torrance CJ
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3880-5. PubMed ID: 17570665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of potent IGF1-R inhibitors related to bis-azaindoles.
    Nemecek C; Metz WA; Wentzler S; Ding FX; Venot C; Souaille C; Dagallier A; Maignan S; Guilloteau JP; Bernard F; Henry A; Grapinet S; Lesuisse D
    Chem Biol Drug Des; 2010 Aug; 76(2):100-6. PubMed ID: 20545947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
    Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
    Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
    Badrinarayan P; Sastry GN
    J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way.
    Uitdehaag JC; Sünnen CM; van Doornmalen AM; de Rouw N; Oubrie A; Azevedo R; Ziebell M; Nickbarg E; Karstens WJ; Ruygrok S
    J Biomol Screen; 2011 Oct; 16(9):1007-17. PubMed ID: 21873591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
    Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
    Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
    Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
    Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
    ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors.
    Peng YH; Shiao HY; Tu CH; Liu PM; Hsu JT; Amancha PK; Wu JS; Coumar MS; Chen CH; Wang SY; Lin WH; Sun HY; Chao YS; Lyu PC; Hsieh HP; Wu SY
    J Med Chem; 2013 May; 56(10):3889-903. PubMed ID: 23611691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.